Novartis AG won approval for the hypertension medicine Tekturna--a potential blockbuster that has shown the ability to lower blood pressure more effectively than common treatments.
Studies have shown that Tekturna is able to keep blood pressure down for more than 24 hours. Elsewhere, Pfizer Inc. (New York) received clearance to promote the cholesterol drug Lipitor, for five new uses to help heart patients and people at risk for stroke. The drug was approved to lower the risk of nonfatal heart attacks, fatal and nonfatal strokes, certain types of heart surgery, hospitalization for heart surgery, and chest pain in patients with heart disease. Quest Diagnostics Inc. (Lyndhurst NJ) won clearance for its herpes simplex virus test. The new Plexus HerpeSelect tests both HSV type-1 and type-2. Respironics Inc. (Murrysville PA) was cleared to sell its Bipap autoSV device for people with breathing problems during sleep. The device uses software to recognize breathing abnormalities and correct them when they occur. And Teva Pharmaceutical Industries Ltd. was cleared to sell a generic version of German drugmaker Schwarz Pharma AG's Uniretic tablets for treating high blood pressure.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||FDA ROUNDUP|
|Date:||Mar 12, 2007|
|Previous Article:||Biovail Corp.|
|Next Article:||Weekly stock performance (as of September 14, 2007).|